Trial Profile
An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydroxyflutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors LIDDS
- 08 Feb 2018 According to a Lidds Pharma media release, results from this and the LPC-003 trials have been published in The Journal of Urology in December 2016.
- 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 21 Jun 2009 New trial record